EUVIMEDEUVIMED entdecken
EditorialKommentar

NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance

Donald W Cockcroft

European Respiratory Journal · 2023

DOI: 10.1183/13993003.02467-2022 ↗

Kurz gefasst

Editorial in der Zeitschrift European Respiratory Journal, 2023. Verfasst von Donald W Cockcroft. Beteiligte Einrichtung: Respiratory Medicine, Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, C…. Hauptthemen laut MEDLINE: Respiration Disorders, Respiratory Tract Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiration DisordersRespiratory Tract DiseasesHumansAspirinAnti-Inflammatory Agents, Non-SteroidalAntibodies, Monoclonal, Humanized

Substanzen

AspirinAnti-Inflammatory Agents, Non-SteroidaldupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Respiratory Medicine, Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada don.cockcroft@usask.ca.

Zitieren

APA

Cockcroft, D. W. (2023). NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance. European Respiratory Journal. https://doi.org/10.1183/13993003.02467-2022

Vancouver

Cockcroft DW. NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance. European Respiratory Journal. 2023. doi:10.1183/13993003.02467-2022

BibTeX
@article{Cockcroft2023,
  author = {Cockcroft, Donald W},
  title = {NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance},
  journal = {European Respiratory Journal},
  year = {2023},
  doi = {10.1183/13993003.02467-2022}
}
Kostenlos starten →